tno155

Advanced Cancer

Mirati Therapeutics Inc.Phase 1Active

CC

40/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 29/ 100
Competitive Position: 73/ 100

Competitive context

1411 Active assets in the Advanced Cancer cohort.

Asset / Sponsor	Phase	Rating
Nabiximols Jazz Pharmaceuticals	Phase 3	BBB
Inno-206 M.D. Anderson Cancer Center	Phase 2	BB
Vitamin B6 M.D. Anderson Cancer Center	Phase 4	BB
PROPOFOL Hong Kong Children's Hospital	Phase 4	BB
Rivoceranib Jiangsu HengRui Medicine Co., Ltd.	Phase 4	BB

View all 50 →

Same molecule, other indications

tno155 is also rated in:

KRAS G12C Mutant Solid TumorsDormant

CC

Indicative ·

45 / 100

colorectal carcinomaDormant

CC

Indicative ·

45 / 100

lung cancerDormant

CC

Indicative ·

45 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.